Your browser doesn't support javascript.
loading
A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure.
Massarweh, Suleiman; Romond, Edward; Black, Esther P; Van Meter, Emily; Shelton, Brent; Kadamyan-Melkumian, Vera; Stevens, Mark; Elledge, Richard.
Affiliation
  • Massarweh S; The Department of Internal Medicine, University of Kentucky, Lexington, KY, USA, massarweh@uky.edu.
Breast Cancer Res Treat ; 143(2): 325-32, 2014 Jan.
Article in En | MEDLINE | ID: mdl-24327334

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Treatment Failure / Sirolimus / Aromatase Inhibitors / Estradiol Type of study: Clinical_trials Limits: Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2014 Document type: Article Country of publication: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Treatment Failure / Sirolimus / Aromatase Inhibitors / Estradiol Type of study: Clinical_trials Limits: Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2014 Document type: Article Country of publication: Netherlands